12:00 AM
May 26, 2016
 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Sirtuin 1 (SIRT1); ataxin 3 (ATXN3)



Patient sample and mouse studies suggest promoting SIRT1 activity could help treat spinocerebellar ataxia type 3 (SCA3), a neurodegenerative disease caused by mutant ATXN3 encoding polyglutamine repeats. Levels of SIRT1 were lower in fibroblasts from SCA3 patients than in fibroblasts from healthy volunteers. In a mouse model of SCA3 that...

Read the full 244 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Innovations

Article Purchase

$35 USD